E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild to moderate Alzheimer's disease |
malattia di Alzheimer di grado da lieve a moderato |
|
E.1.1.1 | Medical condition in easily understood language |
Mild to moderate Alzheimer's disease (dementia) |
malattia di Alzheimer (demenza) da lieve a moderata |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10001897 |
E.1.2 | Term | Alzheimer's disease (incl subtypes) |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029205 |
E.1.2 | Term | Nervous system disorders |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10057167 |
E.1.2 | Term | Mental impairment disorders |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
investigating the effectiveness and safety of nilvadipine as a treatment able to modify the course of Alzheimer's disease of mild to moderate |
indagare l'efficacia e sicurezza di nilvadipina come trattamento in grado di modificare il decorso della malattia di Alzheimer di grado da lieve-moderato |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
OTHER SUBSTUDIES:
Nilvad Frailty Sub study, 06/11 2012, v1 Objective: to define a valid frailty index (FI) in the Nilvad study patients before, during and after treatment.
|
ALTRI SOTTOSTUDI:
Studio ancillare sulla fragilità, 06/11/2012, v1 Obiettivo: definire un valido indicatore di fragilità nei pazienti inclusi nello studio Nilvad
|
|
E.3 | Principal inclusion criteria |
Patients older than 50 years with a diagnosis of Alzheimer's disease according to the NINCDS-ADRDA criteria with a SMMSE test score greater than or equal to 12 and minor than 27. |
Pazienti di età superiore a 50 anni con diagnosi di malattia di Alzheimer secondo i criteri NINCDS-ADRDA con un punteggio al test SMMSE maggiore o uguale a 12 e minore di 27, soggetti in dose stabile (maggiore 3 mesi) inibitori delle colinesterasi e memantina. |
|
E.4 | Principal exclusion criteria |
Subjects treated with calcium-antagonists or beta-blokers, with significant renal or liver impairment, history of significant cardiovascular diseases, such as miocardial infarction or unstable angina. Patients without a caregiver. |
Pazienti attualmente in trattamento con calcio-antagonisti o betabloccanti, con insufficienza renale significativa, grave alterazione della funzione epatica, storia di malattie cardiovascolari significative tra cui recente infarto e angina pectoris instabile. Pazienti senza caregiver. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in cognitive function assessed with the ADAS-Cog 12 scale (Alzheimer's Disease Assessment Scale) and CDR-sb scale (Clinical Dementia Rating Scale sum of boxes) |
Cambiamento della funzione cognitiva valutata con la scala ADAS-Cog 12 (Alzheimer's Disease Assessment Scale) e se significativo la scala CDR-sb (Clinical Dementia Rating Scale sum of boxes) diverrà co-primario |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Change in the performance of activities of daily living assessed with the DAD scale |
Cambiamento nello svolgimento nelle attività della vita quotidiana valutate con la scala DAD (Disability Assessment for Dementia) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 23 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 36 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 36 |
E.8.9.2 | In all countries concerned by the trial days | 0 |